Overview: Torque Teno Virus Quantitative TestIntroduction: The Torque Teno Virus Quantitative Test quantifies TTV to assess immune status, linked to transplant rejection. Aligned with 2023 AST guidelines, it uses PCR for high specificity, supporting transplant screening. This test is critical for guiding immunosuppression monitoring, treatment planning, and improving outcomes in molecular pathology for transplant patients. Note: No specific test parameters provided in input data.
Other Names: TTV Assay, TTV Quantitative PCR Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: TTV testing emerged in the 2000s with transplant immunology research. Quantitative PCR methods improved in the 2010s, enhancing precision.
Purpose: Quantifies TTV to assess immune status, guides immunosuppression, and evaluates transplant rejection risk.
Test Parameters: Not specified in input data; typically includes TTV viral load.
Pretest Condition: No fasting required. Collect whole blood or plasma. Report history of transplant or immunosuppression.
Specimen: Whole Blood (EDTA, 2-5 mL), Plasma (EDTA, 2-4 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document transplant history, rejection episodes, or immunosuppressive therapy. Include current medications, especially immunosuppressants.
Consent: Written consent required, detailing the tests purpose, transplant rejection implications, and risks of sample collection.
Procedural Considerations: Uses quantitative PCR to measure TTV viral load. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for transplant monitoring.
Factors Affecting Result Accuracy: Low DNA yield or contamination can affect results. Sample quality impacts specificity.
Clinical Significance: Elevated TTV levels indicate immune suppression, guiding immunosuppression adjustments. Low levels may suggest over-immunosuppression, increasing infection risk.
Specialist Consultation: Consult a transplant specialist or immunologist for result interpretation and treatment planning.
Additional Supporting Tests: Tacrolimus levels, rejection biomarkers, or kidney function tests to monitor transplant health.
Test Limitations: Non-specific for rejection cause; clinical correlation is needed. Sample quality affects sensitivity.
References: AST Transplant Guidelines, 2023; Transplantation, Maggi F, 2022.
